Combined treatment with terbutaline and aminophylline inhibits experimental amyloidosis in mice

Arthritis Rheum. 1994 Dec;37(12):1757-60. doi: 10.1002/art.1780371208.

Abstract

Objective: To investigate the effects of drugs known to elevate adenosine 3':5'-cyclic monophosphate (cAMP) on experimental amyloidosis.

Methods: A beta 2-agonist, terbutaline, and a phosphodiesterase inhibitor, aminophylline, were administered in combination in a mouse model of amyloidosis induced by inflammatory stimulation with silver nitrate. Amyloidosis was quantitated by radioimmunoassay for splenic amyloid A (AA) protein.

Results: At the doses selected, aminophylline/terbutaline inhibited splenic amyloid deposition more potently than did colchicine, a known inhibitor of amyloidosis.

Conclusion: Drugs known to elevate cAMP inhibit experimental mouse AA amyloidosis.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adrenergic beta-Agonists / pharmacology
  • Aminophylline / therapeutic use*
  • Amyloidosis / prevention & control*
  • Animals
  • Cyclic AMP / analysis
  • Drug Therapy, Combination
  • Female
  • Mice
  • Mice, Inbred CBA
  • Phosphodiesterase Inhibitors / pharmacology
  • Pilot Projects
  • Serum Amyloid A Protein / analysis
  • Spleen / chemistry
  • Terbutaline / therapeutic use*

Substances

  • Adrenergic beta-Agonists
  • Phosphodiesterase Inhibitors
  • Serum Amyloid A Protein
  • Aminophylline
  • Cyclic AMP
  • Terbutaline